设为首页 |  加入收藏 |  联系我们

如:神经外科 骨科 手外科 眼科 神经内科……

Outcome of endoscopic trans-ethmosphenoid optic canal decompression combined with steroid

发布日期:2016-11-01 点击次数:1229 字体显示:【大】  【中】  【小】

Outcome of endoscopic trans-ethmosphenoid optic canal decompression combined with steroid and nerve growth factor therapy for short - time traumatic optic neuropathy

【Author】 Bo Yu, Can Gong, Ying-Jie Ma, Wen-Can Wu

 

【Author information】

Department of Orbital & Oculoplastic Surgery, Eye Hospitalof Wenzhou Medical University, Wenzhou 325027, Zhejiang Province, China

Department of Ophthalmology, Loudi Central Hospital, Loudi 417000, Hunan Province, China

 

【Abstract】

AIM: To present the efficacy of Endoscopic trans -ethmosphenoid optic canal decompression ( ETOCD ) combined with steroid and nerve growth factor (NGF) therapy in patients with short - time traumatic optic neuropathy(TON). METHODS: A retrospective analysis of 151 TON patients (151 eyes) were performed. Their first treatment were all initiated within 5 days of injury. All patients were treated with methylprednisolone for 3 days. There were 117 patients did not improve with methylprednisolone treatment were offered ETOCD. Local and systemic administration of steroid and NGF were given to them after surgery. According to the visual acuity ( VA ) preoperatively, all patients who underwent surgery were divided into Group A [no light perception (NLP)] and Group B (with residual vision). RESULTS: VA was improved in 70 of 117 patients after surgery, with a total efficacy of 59. 8% . The effective rate of Group A and B were 44. 8% and 80. 0% respectively. Group B had significantly higher effectiveness rate than Group A (x2 = 14. 781, P<0. 05). CONCLUSION: ETOCD combined with steroid and NGF may be an useful way to improve VA in short- time TON patients. Patients with preoperative residual vision had better prognosis in VA postoperatively. However, NLP patients may benefit from surgery as well.
誗KEYWORDS: endoscopic trans - ethmosphenoid optic canal decompression; steroid; nerve growth factor

DOI:10. 3980/ j. issn. 1672-5123. 2016. 11. 01